WGM informs me that Gilead’s latest foray into bug juice is turning up some workable numbers. As usual, the press release is notable for what it doesn’t reveal. That always concerns me.
An example:
In the small percentage of patients with cirrhosis at baseline who received sofosbuvir/RBV, 61% achieved SVR12. All patients receiving sofosbuvir/RBV became HCV RNA negative on treatment and relapse accounted for all virologic failures.
The above in blue means nobody is liable to keel over after eating it like WGH and I are prone to. What also surprises me is that Genotype 3, usually one of the easiest to overwhelm, has the poorest response rate of all.
SVR12 rates were 93% in genotype 2 and 61% in genotype 3.
I’m still betting on DRACO. My AIH is kicking ass and taking names with me right now. Between that and the dragon, the going’s a little rough.
Bug juice for seniors
asknod
Bethanie Spangenberg
kcraveiro
robinhoodesqvetsatty
Wesley McCauley
Veterans Claims Help 
How can a patient get in on this study?
“ION-2: Gilead today announced that a second Phase 3 study for sofosbuvir/GS-5885, ION-2, is expected to begin screening patients in January 2013. This study will evaluate the fixed-dose combination, with RBV for 12 weeks and with and without RBV for 24 weeks of therapy among 400 treatment-experienced genotype 1 HCV patients. Participants in this study will have failed past therapy with regimens containing IFN or IFN plus a protease inhibitor.”
——————————
Hmmm, that image of a dragon. I read this quote somewhere on the net the other day and saved it. “To to conquer the dragon, the skin must be penetrated.” This new weapon sounds promising.